Supporting his view, Citigroup analyst Geoff Meacham, on Wednesday, maintained Eli Lilly with a Buy and increased the price target from $1,500 to $1,600.
Rob Sechan, CEO of NewEdge Wealth, picked Vistra Corp. (NYSE:VST).
Lending support to his choice, Scotiabank analyst Andrew Weisel, on Wednesday, maintained Vistra with a Sector Outperform and raised the price target from $293 to $298.
Don’t forget to check out our premarket coverage here
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, recommended Meta Platforms, Inc. (NASDAQ:META).
Meta Platforms will release second-quarter financial results after the closing bell on Wednesday, July 29. Analysts expect the company to report quarterly earnings at $7.20 per share on revenue of $60.24 billion.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, named T. Rowe Price Group, Inc. (NASDAQ:TROW) as his final trade.
Barclays analyst Benjamin Budish, on Tuesday, maintained T. Rowe Price Group with an Underweight rating and raised the price target from $89 to $108.
Price Action:
- T. Rowe Price shares rose 2.2% to close at $118.58 on Wednesday.
- Vistra shares gained 1.1% to settle at $160.23 during the session.
- Meta shares gained 3.1% to close at $681.31 on Wednesday.
- Eli Lilly shares rose 0.4% to settle at $1,156.63 during the session.
Photo via Shutterstock